| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= mean pre‐dose sitting DBP 100‐115 mm Hg after 3 and 4 weeks of run‐in, mean baseline DBP >/= 100 mm Hg at hourly measurements 21‐24 h post‐placebo and also during whole BP profile (i.e. hourly measurements 1‐8 h and 21‐24 h post‐dose); 8‐week double‐blind treatment |
| Participants |
Cilazapril 1 mg: n=42(26 males,16 females); mean age=53 years; baseline sitting BP not reported;
Cilazapril 2.5 mg: n=42(28 males,14 females); mean age=52 years; baseline sitting BP not reported;
Cilazapril 5 mg: n=42(27 males,15 females); mean age=48 years; baseline sitting BP not reported;
Placebo: n=43(22 males,21 females); mean age=56 years; baseline sitting BP not reported |
| Interventions |
Cilazapril 1 mg once daily;
Cilazapril 2.5 mg once daily;
Cilazapril 5 mg once daily;
Placebo;
taken at approximately 12 noon before meal |
| Outcomes |
Mean change from baseline in trough sitting DBP using mercury sphygmomanometer |
| Notes |
SBP change not reported; DBP change and SE of change reported, endpoint DBP and SD not reported; calculated DBP SD of change from N and SE of change; BP data from text, p. 224; Jadad score=2; funding source= Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
